{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T10:21:55Z","timestamp":1700562115184},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2020,1,12]],"date-time":"2020-01-12T00:00:00Z","timestamp":1578787200000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,11,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>We perform an econometric assessment of the impact that pharmaceutical innovation had on the burden of disease in Ireland.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We use a difference-in-differences (or two-way fixed effects) research design: we investigate whether diseases for which more new drugs were launched had larger subsequent reductions in mortality. This design controls for the effects of general economic and societal factors (e.g. income, education, and behavioral risk factors), to the extent that those effects are similar across diseases.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>New Chemical Entities launched during 1983\u20131997 are estimated to have reduced the total number of disability-adjusted life-years (DALYs) lost in 2015 by about 234 600.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Pharmaceutical expenditure per DALY gained in 2015 from drugs launched during 1983\u20131997 was \u20ac1137, which indicates that the new drugs launched during 1983\u20131997 were very cost\u2013effective, overall.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/pubmed\/fdz183","type":"journal-article","created":{"date-parts":[[2019,12,12]],"date-time":"2019-12-12T20:11:16Z","timestamp":1576181476000},"page":"816-827","source":"Crossref","is-referenced-by-count":3,"title":["The impact of pharmaceutical innovation on the burden of disease in Ireland, 2000\u20132015"],"prefix":"10.1093","volume":"42","author":[{"given":"Frank R","family":"Lichtenberg","sequence":"first","affiliation":[{"name":"Columbia University, New York, NY 10027, USA"},{"name":"National Bureau of Economic Research, Cambridge, MA 02138, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,1,11]]},"reference":[{"key":"2020120619090135900_ref1","doi-asserted-by":"publisher","DOI":"10.1787\/9789264283435-en","volume-title":"Ireland: Country Health Profile 2017, State of Health in the EU","author":"OECD\/European Observatory on Health Systems and Policies","year":"2017"},{"issue":"3","key":"2020120619090135900_ref2","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1257\/jep.20.3.97","article-title":"The determinants of mortality","volume":"20","author":"Cutler","year":"2006","journal-title":"J Econ Perspect"},{"key":"2020120619090135900_ref3","volume-title":"Mathematical Methods in the Social Sciences, 1959","author":"Solow","year":"1960"},{"key":"2020120619090135900_ref4","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0304-3932(97)00065-2","article-title":"The 'embodiment' controversy: a review essay","volume":"41","author":"Hercowitz","year":"1998","journal-title":"J Monet Econ"},{"key":"2020120619090135900_ref5","volume-title":"Introduction to Economic Growth","author":"Jones","year":"1998"},{"issue":"2","key":"2020120619090135900_ref6","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1001\/jama.2009.1987","article-title":"Financial anatomy of biomedical research, 2003\u20132008","volume":"303","author":"Dorsey","year":"2010","journal-title":"J Am Med Assoc"},{"key":"2020120619090135900_ref7","article-title":"WHO methods and data sources for global burden of disease estimates 2000-2016","author":"World Health Organization","year":"2019"},{"issue":"8","key":"2020120619090135900_ref8","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1002\/hec.855","article-title":"The productivity of health care and health production functions","volume":"13","author":"Ko\u00e7","year":"2004","journal-title":"Health Econ"},{"issue":"1","key":"2020120619090135900_ref9","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1257\/000282802760015685","article-title":"Sources of U.S. economic growth in a world of ideas","volume":"92","author":"Jones","year":"2002","journal-title":"Am Econ Rev"},{"issue":"3","key":"2020120619090135900_ref10","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1162\/0033553041502144","article-title":"Market size in innovation: Theory and evidence from the pharmaceutical industry","volume":"119","author":"Acemoglu","year":"2004","journal-title":"Q J Econ"},{"issue":"3","key":"2020120619090135900_ref11","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/hec.931","article-title":"The impact of price regulation on the launch delay of new drugs\u2014Evidence from twenty-five major markets in the 1990s","volume":"14","author":"Danzon","year":"2005","journal-title":"Health Econ"},{"key":"2020120619090135900_ref12","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1017\/dem.2018.11","article-title":"The impact of new drug launches on life-years lost in 2015 from 19 types of cancer in 36 countries","volume":"84","author":"Lichtenberg","year":"2018","journal-title":"J Demographic Econ"},{"issue":"2","key":"2020120619090135900_ref13","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1377\/hlthaff.2009.0917","article-title":"What are the respective roles of the public and private sectors in pharmaceutical innovation?","volume":"30","author":"Sampat","year":"2011","journal-title":"Health Aff"},{"key":"2020120619090135900_ref14","article-title":"Enhancing drug discovery and development","author":"National Cancer Institute","year":"2019"},{"issue":"1","key":"2020120619090135900_ref15","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1093\/cesifo\/ift014","article-title":"Has medical innovation reduced cancer mortality?","volume":"60","author":"Lichtenberg","year":"2014","journal-title":"CESifo Econ Stud"},{"key":"2020120619090135900_ref16","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ehb.2013.04.002","article-title":"The impact of pharmaceutical innovation on longevity and medical expenditure in France, 2000\u20132009","volume":"13","author":"Lichtenberg","year":"2014","journal-title":"Econ Human Biol"},{"key":"2020120619090135900_ref17","article-title":"Surgery for blocked arteries is often unwarranted, researchers find","author":"Kolata","year":"2019","journal-title":"New York Times"},{"key":"2020120619090135900_ref18","article-title":"The pharmaceutical industry and Global Health: facts and figures 2017","author":"International Federation of Pharmaceutical Manufacturers & Associations","year":"2017"},{"issue":"12","key":"2020120619090135900_ref19","doi-asserted-by":"crossref","first-page":"925","DOI":"10.2471\/BLT.15.164418","article-title":"Cost-effectiveness thresholds: pros and cons","volume":"94","author":"Bertram","year":"2016","journal-title":"Bull World Health Organ"},{"key":"2020120619090135900_ref20","article-title":"New medicines for patients as fast as in Europe: need for sustained funding growth","author":"Irish Pharmaceutical Healthcare Association","year":"2018"},{"key":"2020120619090135900_ref21","article-title":"Disease burden and mortality estimates: cause-specific mortality, 2000\u20132016","author":"World Health Organization","year":"2019"},{"key":"2020120619090135900_ref22","article-title":"Disease burden and mortality estimates: disease burden, 2000\u20132016","author":"World Health Organization","year":"2019"},{"key":"2020120619090135900_ref23","article-title":"Th\u00e9riaque database","author":"Centre National Hospitalier d\u2019Information sur le M\u00e9dicament","year":"2019"}],"container-title":["Journal of Public Health"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jpubhealth\/article-pdf\/42\/4\/816\/34469235\/fdz183.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jpubhealth\/article-pdf\/42\/4\/816\/34469235\/fdz183.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,7]],"date-time":"2020-12-07T00:56:40Z","timestamp":1607302600000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jpubhealth\/article\/42\/4\/816\/5700764"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,11]]},"references-count":23,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,1,11]]},"published-print":{"date-parts":[[2020,11,23]]}},"URL":"https:\/\/doi.org\/10.1093\/pubmed\/fdz183","relation":{},"ISSN":["1741-3842","1741-3850"],"issn-type":[{"value":"1741-3842","type":"print"},{"value":"1741-3850","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,12]]},"published":{"date-parts":[[2020,1,11]]}}}